Premium
HIV‐Associated Lipodystrophy Syndrome
Author(s) -
Qaqish Roula B.,
Fisher Evelyn,
Rublein John,
Wohl David A.
Publication year - 2000
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1592/phco.20.1.13.34667
Subject(s) - lipodystrophy , medicine , antiretroviral therapy , diabetes mellitus , human immunodeficiency virus (hiv) , reverse transcriptase , adverse effect , protease inhibitor (pharmacology) , nucleoside reverse transcriptase inhibitor , metabolic syndrome , virology , immunology , viral load , biology , endocrinology , rna , biochemistry , gene
Highly active antiretroviral therapy (HAART) for human immunodeficiency virus‐1 (HIV‐1) and prophylactic therapy for opportunistic infections have increased survival. Adverse effects of HAART include lipid profile alterations, diabetes mellitus, and fat redistribution. These metabolic and physical changes are called the HIV‐associated lipodystrophy syndrome. A link to protease inhibitors has been suggested, and more recently to nucleoside reverse transcriptase inhibitors and factors related to duration of HIV‐1 infection itself.